-
Mashup Score: 44Adrenal-Permissive HSD3B1 Genotype and Prostate Cancer Mortality - 9 month(s) ago
Prostate cancer progression is dependent on androgen receptor signaling, which is activated by the circulating gonadal androgen testosterone and its more potent metabolite, 5α-dihydrotestosterone (DHT), generated from testosterone in the prostate. Androgen deprivation therapy (ADT) leading to the…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 98HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES - 9 month(s) ago
Sharifi et al. demonstrate that, in metastatic hormone-sensitive prostate cancer (mHSPC), there are no differences in clinical outcomes, largely evaluable in high-volume disease, between men with the adrenal-permissive genotype and those with the adrenal-restrictive genotype of HSD3B1. Enzalutamide therapy provides clinical benefit independent of the HSD3B1 genotype.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
1/6 Very glad that our story on HSD3B1 and clinical outcomes with ADT+enzalutamide in ARCHES is finally out in @CellRepMed with @AarmstrongDuke @AzadOncology @AStenzl @DSUI_Miami_Uro @SylvesterCancer @PCF_Science! https://t.co/lmkipMO8D7
-
-
Mashup Score: 6Adrenal-Permissive HSD3B1 Allele and Prostate Cancer Outcomes - 9 month(s) ago
This cohort study analyzes the association of HSD3B1 status with prostate cancer outcomes among patients in the Veterans Affairs Health System in the US.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
3/3 Read MVP paper here & our commentary. Unlike other intermediate monogenic drivers of mortality (BRCA2, etc.), there’s no assoc b/t HSD3B1 & intermediate clinical factors, e.g., path. Effect on outcomes & mortality ONLY after ADT. Time to start use IMO! https://t.co/4ez6AIkKN4
-
-
Mashup Score: 4
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to tes…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
5/12 But is there anything that can be done about it, particularly in men with LV mHSPC? What if we block the effect of non-gonadal androgens upfront (with enzalutamide or NSAA)? ENZAMET @ANZUPtrials seemed perfect to answer this question! https://t.co/JQ2Y8bElDn https://t.co/Dz7fUZGZ1V
-
-
Mashup Score: 6HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer - 9 month(s) ago
This study examines the development and outcomes of men with the HSD3B1 genotype receiving treatment for metastatic prostate cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
2/6 What did we know before this study? Men with adrenal-permissive (hyperactive) HSD3B1 enzyme and low volume (LV) metastatic prostate cancer progress more quickly and have shorter survival when hormonal therapy is ADT (or castration) alone – from E3805 https://t.co/T247SxWsDO https://t.co/UJy4icwviW
-
-
Mashup Score: 4A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer - 9 month(s) ago
Dihydrotestosterone (DHT), a potent androgen secreted by the testis, promotes the development of prostate cancer. Castration limits tumor growth, but castration-resistant tumors often recur. A gain-of-stability mutation in the enzyme 3βHSD1, an upstream regulator of DHT biosynthesis, drives this resistance and may be a valid therapeutic target.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
2/12 Worth emphasizing again that the missense-encoding HSD3B1 adrenal-permissive allele effectively increases activity for the first and rate-limiting step for pca to make DHT from non-gonadal precursors. It is inherited in 50% of all men! @CellCellPress https://t.co/HpEvyXijIH
-
-
Mashup Score: 24
The Desai Sethi Urology Institute seeks to recruit an outstanding scientist with experience in fundamental mechanisms of human biology.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Are you doing exciting mechanistic science or translational work? Join us in #Miami! We are looking for independent investigators at all levels! @ASBMB @thepostdoctoral @AACR Faculty Positions - U of Miami @umiamimedicine https://t.co/MUAp3m9LNy
-
-
Mashup Score: 39Episode 341: Hormone Resistance in Prostate Cancer by The Uromigos - 10 month(s) ago
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
Source: podcasters.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Thank you @brian_rini and @tompowles1 for inviting me to discuss prostate cancer hormonal therapy resistance on @Uromigos! https://t.co/eRQP8NXKzs
-
-
Mashup Score: 2How to Find the Right Oncologist for You - 10 month(s) ago
After a cancer diagnosis, it’s one of the most important decisions you’ll make.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
How to Find the Right Oncologist for You https://t.co/JsI5LJyrap
-
-
Mashup Score: 5HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer - 10 month(s) ago
This study examines the development and outcomes of men with the HSD3B1 genotype receiving treatment for metastatic prostate cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
2/6 What did we know before this study? Men with adrenal-permissive (hyperactive) HSD3B1 enzyme and low volume (LV) metastatic prostate cancer progress more quickly and have shorter survival when hormonal therapy is ADT (or castration) alone – from E3805 https://t.co/T247SxWsDO https://t.co/UJy4icwviW
-
1/3 Congrats @DrRanaMcKay & MVP on @JAMANetworkOpen story showing HSD3B1⬆️prostate ca mortality in 5200 men! MVP suggests HSD3B1 is most common inherited driver of prostate ca mortality. Our commentary @SchifferLina explains our long obsession w/HSD3B1! https://t.co/BZxxpqnxmb